- Home
- STKS vs AVTX Comparison
STKS vs AVTX Comparison
Compare STKS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- AVTX
- Stock Information
- Founded
- STKS 2004
- AVTX 2011
- Country
- STKS United States
- AVTX United States
- Employees
- STKS N/A
- AVTX N/A
- Industry
- STKS Restaurants
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- AVTX Health Care
- Exchange
- STKS Nasdaq
- AVTX Nasdaq
- Market Cap
- STKS 100.6M
- AVTX 88.4M
- IPO Year
- STKS N/A
- AVTX 2015
- Fundamental
- Price
- STKS $2.99
- AVTX $8.46
- Analyst Decision
- STKS Buy
- AVTX Strong Buy
- Analyst Count
- STKS 2
- AVTX 7
- Target Price
- STKS $4.25
- AVTX $34.33
- AVG Volume (30 Days)
- STKS 73.4K
- AVTX 110.1K
- Earning Date
- STKS 03-10-2025
- AVTX 05-12-2025
- Dividend Yield
- STKS N/A
- AVTX N/A
- EPS Growth
- STKS N/A
- AVTX N/A
- EPS
- STKS N/A
- AVTX N/A
- Revenue
- STKS $673,344,000.00
- AVTX $441,000.00
- Revenue This Year
- STKS $28.47
- AVTX N/A
- Revenue Next Year
- STKS N/A
- AVTX N/A
- P/E Ratio
- STKS N/A
- AVTX N/A
- Revenue Growth
- STKS 102.35
- AVTX N/A
- 52 Week Low
- STKS $2.37
- AVTX $5.99
- 52 Week High
- STKS $6.10
- AVTX $22.47
- Technical
- Relative Strength Index (RSI)
- STKS 52.53
- AVTX 56.89
- Support Level
- STKS $2.83
- AVTX $7.88
- Resistance Level
- STKS $3.04
- AVTX $9.00
- Average True Range (ATR)
- STKS 0.18
- AVTX 0.81
- MACD
- STKS 0.05
- AVTX 0.12
- Stochastic Oscillator
- STKS 92.54
- AVTX 54.41
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Kona Grill, ONE Hospitality, and Corporate. The company generates the vast majority of its revenue from the domestic market.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).